Singapore-based firm to start human trials for Covid-19 treatment
Team Udayavani, Jun 12, 2020, 11:02 AM IST
Tychan, Singaporean biotechnology firm, will begin human clinical trials next week for a potential monoclonal antibody treatment for Covid-19
The first phase of the trial will be conducted on healthy volunteers to determine the safety and tolerability of TY027, a monoclonal antibody or immune system protein that specifically targets the virus that causes Covid-19.
TY027 is being explored for its ability to slow down the progression of Covid-19 and speed up recovery, and its potential to provide temporary protection against infection
It is said that if phase one is successful, Tychan will seek approval for the antibody to be administered to a larger population of volunteer patients in subsequent trials.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Intruder killed along India-Pakistan border in Rajasthan
Kazakhstan says 42 people likely dead in Azerbaijan Airlines’ plane crash
Killed in Russia-Ukraine war six months ago, UP man’s body brought back home
‘We should try again’: Punjab Assembly Speaker on Vajpayee’s failed India-Pak peace initiative
Delhi Police crackdown on illegal immigration of Bangladeshi citizens, 11 arrested
MUST WATCH
Latest Additions
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.